THOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday , Dec. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME. For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2024-global-healthcare-conference-302319891.html SOURCE AmgenUS to send $1.25 billion in weapons to Ukraine, pushing to get aid out before Biden leaves office WASHINGTON (AP) — The United States is expected to announce that it will send $1.25 billion in military assistance to Ukraine, U.S. officials said Friday, as the Biden administration pushes to get as much aid to Kyiv as possible before leaving office on Jan. 20. The large package of aid includes a significant amount of munitions, including for the National Advanced Surface-to-Air Missile Systems and the HAWK air defense system. It also will provide Stinger missiles and 155 mm- and 105 mm artillery rounds, officials said. The officials, who said they expect the announcement to be made on Monday, spoke on condition of anonymity to provide details not yet made public. The new aid comes as Russia has launched a barrage of attacks against Ukraine’s power facilities in recent days, although Ukraine has said it intercepted a significant number of the missiles and drones. Russian and Ukrainian forces are also still in a bitter battle around the Russian border region of Kursk, where Moscow has sent thousands of North Korean troops to help reclaim territory taken by Ukraine. Earlier this month, senior defense officials acknowledged that that the Defense Department may not be able to send all of the remaining $5.6 billion in Pentagon weapons and equipment stocks passed by Congress for Ukraine before President-elect Donald Trump is sworn in. An online debate over foreign workers in tech shows tensions in Trump's political coalition WEST PALM BEACH, Fla. (AP) — An online spat between factions of Donald Trump's supporters over immigration and the tech industry has thrown internal divisions in his political movement into public display, previewing the fissures and contradictory views his coalition could bring to the White House. The rift laid bare the tensions between the newest flank of Trump's movement — wealthy members of the tech world including billionaire Elon Musk and fellow entrepreneur Vivek Ramaswamy and their call for more highly skilled workers in their industry — and people in Trump's Make America Great Again base who championed his hardline immigration policies. The debate touched off this week when Laura Loomer, a right-wing provocateur with a history of racist and conspiratorial comments, criticized Trump’s selection of Sriram Krishnan as an adviser on artificial intelligence policy in his coming administration. Krishnan favors the ability to bring more skilled immigrants into the U.S. Loomer declared the stance to be “not America First policy” and said the tech executives who have aligned themselves with Trump were doing so to enrich themselves. Much of the debate played out on the social media network X, which Musk owns. A 9th telecoms firm has been hit by a massive Chinese espionage campaign, the White House says WASHINGTON (AP) — A ninth U.S. telecoms firm has been confirmed to have been hacked as part of a sprawling Chinese espionage campaign that gave officials in Beijing access to private texts and phone conversations of an unknown number of Americans, a top White House official said Friday. Biden administration officials said this month that at least eight telecommunications companies, as well as dozens of nations, had been affected by the Chinese hacking blitz known as Salt Typhoon. But deputy national security adviser Anne Neuberger told reporters Friday that a ninth victim had been identified after the administration released guidance to companies about how to hunt for Chinese culprits in their networks. The update from Neuberger is the latest development in a massive hacking operation that has alarmed national security officials, exposed cybersecurity vulnerabilities in the private sector and laid bare China's hacking sophistication. The hackers compromised the networks of telecommunications companies to obtain customer call records and gain access to the private communications of what officials have said is a a limited number of individuals. Though the FBI has not publicly identified any of the victims, officials believe senior U.S. government officials and prominent political figures are among those whose whose communications were accessed. Warren Upton, the oldest living survivor of the attack on Pearl Harbor, dies at 105 HONOLULU (AP) — Warren Upton, the oldest living survivor of the 1941 Japanese attack on Pearl Harbor and the last remaining survivor of the USS Utah, has died. He was 105. Upton died Wednesday at a hospital in Los Gatos, California, after suffering a bout of pneumonia, said Kathleen Farley, the California state chair of the Sons and Daughters of Pearl Harbor Survivors. The Utah, a battleship, was moored at Pearl Harbor when Japanese planes began bombing the Hawaii naval base in the early hours of Dec. 7, 1941, in an attack that propelled the U.S. into World War II. Upton told The Associated Press in 2020 that he had been getting ready to shave when he felt the first torpedo hit the Utah. He recalled that no one on board knew what made the ship shake. Then, the second torpedo hit and the ship began to list and capsize. The then-22-year-old swam ashore to Ford Island, where he jumped in a trench to avoid Japanese planes strafing the area. He stayed for about 30 minutes until a truck came and took him to safety. Israeli troops forcibly remove staff and patients from northern Gaza hospital, officials say DEIR AL-BALAH, Gaza Strip (AP) — Israeli troops stormed one of the last hospitals operating in northern Gaza on Friday, forcing many staff and patients outside to strip in winter weather, the territory’s health ministry said. The army denied claims it had entered or set fire to the complex and accused Hamas of using the facility for cover. Kamal Adwan Hospital has been hit multiple times over the past three months by Israeli troops waging an offensive against Hamas fighters in surrounding neighborhoods, according to staff. The ministry said a strike on the hospital a day earlier killed five medical staff. Israel's military said it was conducting operations against Hamas infrastructure and militants in the area and had ordered people out of the hospital, but said it had not entered the complex as of Friday night. It repeated claims that Hamas militants operate inside Kamal Adwan but provided no evidence. Hospital officials have denied that. The Health Ministry said troops forced medical personnel and patients to assemble in the yard and remove their clothes. Some were led to an unknown location, while some patients were sent to the nearby Indonesian Hospital, which was knocked out of operation after an Israel raid this week. Israeli troops during raids frequently carry out mass detentions, stripping men to their underwear for questioning in what the military says is a security measure as they search for Hamas fighters. Azerbaijani and U.S. officials suggest plane that crashed may have been hit by weapons fire Russian air defense systems may have brought down an Azerbaijani airliner this week, a U.S. official said Friday after an Azerbaijani minister also suggested the plane was hit by a weapon, citing expert analysis and survivor accounts. Friday's assessments by Rashan Nabiyev and White House national security spokesman John Kirby echoed those made by outside aviation experts who blamed the crash on Russian air defense systems responding to a Ukrainian attack. These statements raised pressure on Russia, where officials said a drone attack was underway in the region where the Azerbaijan Airlines flight was heading for a landing. They did not address statements blaming air defenses. Kirby told reporters on Friday that the U.S. "have seen some early indications that would certainly point to the possibility that this jet was brought down by Russian air defense systems,” but refused to elaborate, citing an ongoing investigation. Pressed on whether the U.S. has intelligence that helped lead to that conclusion, or was simply relying on informed speculation from experts based on visual assessments of the crash, Kirby characterized the short answer as “yes” but said he’d “leave it at that,” without providing further details. The plane was flying from Azerbaijan’s capital of Baku to Grozny, the regional capital of the Russian republic of Chechnya, on Wednesday when it turned toward Kazakhstan and crashed while making an attempt to land. The crash killed 38 people and left all 29 survivors injured. Court rules Georgia lawmakers can subpoena Fani Willis for information related to her Trump case ATLANTA (AP) — A judge has ruled that the Georgia state Senate can subpoena Fulton County District Attorney Fani Willis as part of a inquiry into whether she has engaged in misconduct during her prosecution of President-elect Donald Trump but is giving Willis the chance to contest whether lawmakers' demands are overly broad. Fulton County Superior Court Judge Shukura Ingram filed the order Monday, telling Willis she has until Jan. 13 to submit arguments over whether the subpoenas seek legally shielded or confidential information. Ingram wrote that the would issue a final order later saying what Willis had to respond to. Willis, though, wants the ruling overturned. “We believe the ruling is wrong and will appeal,” former Georgia Gov. Roy Barnes, who is representing Willis in the case, wrote in an email to The Associated Press. A state appeals court earlier this month removed Willis from the Georgia election interference case against Donald Trump and others, citing an “appearance of impropriety” that might not typically warrant such a removal. The Georgia Court of Appeals panel said in a 2-1 ruling that because of the romantic relationship Willis had with special prosecutor Nathan Wade “this is the rare case in which disqualification is mandated and no other remedy will suffice to restore public confidence in the integrity of these proceedings.” US homelessness up 18% as affordable housing remains out of reach for many people The United States saw an 18.1% increase in homelessness this year, a dramatic rise driven mostly by a lack of affordable housing as well as devastating natural disasters and a surge of migrants in several parts of the country, federal officials said Friday. The U.S. Department of Housing and Urban Development said federally required tallies taken across the country in January found that more than 770,000 people were counted as homeless — a number that misses some people and does not include those staying with friends or family because they do not have a place of their own. That increase comes on top of a 12% increase in 2023, which HUD blamed on soaring rents and the end of pandemic assistance. The 2023 increase also was driven by people experiencing homelessness for the first time. The numbers overall represent 23 of every 10,000 people in the U.S., with Black people being overrepresented among the homeless population. “No American should face homelessness, and the Biden-Harris Administration is committed to ensuring every family has access to the affordable, safe, and quality housing they deserve,” HUD Agency Head Adrianne Todman said in a statement, adding that the focus should remain on “evidence-based efforts to prevent and end homelessness.” Among the most concerning trends was a nearly 40% rise in family homelessness — one of the areas that was most affected by the arrival of migrants in big cities. Family homelessness more than doubled in 13 communities impacted by migrants including Denver, Chicago and New York City, according to HUD, while it rose less than 8% in the remaining 373 communities. Nearly 150,000 children experienced homelessness on a single night in 2024, reflecting a 33% jump from last year. What Snoop wants: Arizona Bowl gives NIL opportunities to players for Colorado State, Miami (Ohio) TUCSON, Ariz. (AP) — Snoop Dogg has nearly as many ties to football as he does to rap music. The entertainer coached youth football for years and created the Snoop League, an after-school program for inner city Los Angeles youths. Snoop has been a guest analyst on football broadcasts and his son, Cordell Broadus, played Division I football. When Snoop took his latest step, becoming the sponsor of a bowl game, he had a demand: Find a way for all players in the game to receive name, image and likeness (NIL) money. “This was Snoop's idea,” said Kym Adair, executive director of the Snoop Dogg Arizona Bowl presented by Gin & Juice. “He was having conversations with people he knows in the college football world and I got a call that said he wants us to be the first bowl to make this commitment and that's what we did.” The beneficiaries are Colorado State and Miami (Ohio), who will conclude their seasons Saturday at Arizona Stadium in the Arizona Bowl. The bowl is classified as a 501(c)(3), so all revenue goes to charity. And, being one of the few bowls not tied to ESPN, it opens the door for unique sponsorship opportunities. Alex Ovechkin is on track to break Wayne Gretzky's NHL career goals record Alex Ovechkin of the Washington Capitals is closing in on the NHL career goals record of 894 held by Wayne Gretzky. Ovechkin has 868 goals after scoring 15 in the first 18 games this season. He needs 27 to set a new record. Ovechkin entered the season 42 short of breaking a record by “The Great One” that long seemed unapproachable. The 39-year-old Russian is in his 20th NHL season and was on pace to get to 895 in February before breaking his left leg in a shin-on-shin collision in November. Ovechkin could resume his pursuit as soon as Saturday night at Toronto in the Capitals' first game out of the Christmas break. Ovechkin scored twice in a 6-2 win over the Utah Hockey Club on Nov. 18, getting goals 867 and 868 in his first game in Salt Lake City before leaving in the third period. Ovechkin seems on track to play Saturday at the Maple Leafs. He has scored 44 goals against them during his career, tied for the fifth-most among all opponents. Copyright 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.Bianca Ojukwu speaks on Tinubu releasing IPOB leader Nnamdi Kanu
casino games vegas
。
Cabinet to OK ¥39 tril economic package to ease price pain
GSA Capital Partners LLP Sells 77,629 Shares of MINISO Group Holding Limited (NYSE:MNSO)
Mutual of America Capital Management LLC reduced its position in shares of Masimo Co. ( NASDAQ:MASI – Free Report ) by 6.5% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 23,865 shares of the medical equipment provider’s stock after selling 1,667 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Masimo were worth $3,182,000 as of its most recent SEC filing. Several other hedge funds also recently modified their holdings of the company. NBC Securities Inc. lifted its holdings in shares of Masimo by 47.1% in the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 73 shares during the period. GAMMA Investing LLC boosted its position in shares of Masimo by 75.0% during the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 111 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in shares of Masimo by 133.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 200 shares during the last quarter. HHM Wealth Advisors LLC raised its holdings in shares of Masimo by 25.0% in the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock worth $79,000 after purchasing an additional 125 shares in the last quarter. Finally, Lazard Asset Management LLC lifted its stake in Masimo by 5,730.0% during the first quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock valued at $85,000 after purchasing an additional 573 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors and hedge funds. Analysts Set New Price Targets Several research analysts have issued reports on MASI shares. Stifel Nicolaus reaffirmed a “buy” rating and issued a $190.00 price target (up previously from $170.00) on shares of Masimo in a report on Friday. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. BTIG Research lifted their price target on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Wells Fargo & Company boosted their price objective on Masimo from $160.00 to $171.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. Finally, Piper Sandler lifted their target price on shares of Masimo from $165.00 to $180.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $167.00. Masimo Stock Performance MASI stock opened at $172.96 on Friday. The firm has a 50 day simple moving average of $142.28 and a 200 day simple moving average of $127.76. Masimo Co. has a 52 week low of $91.60 and a 52 week high of $174.34. The stock has a market cap of $9.26 billion, a P/E ratio of 119.28 and a beta of 0.97. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. Masimo ( NASDAQ:MASI – Get Free Report ) last posted its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, beating the consensus estimate of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $504.60 million for the quarter, compared to analysts’ expectations of $502.87 million. During the same period in the previous year, the company posted $0.63 EPS. Masimo’s revenue was up 5.4% on a year-over-year basis. Research analysts anticipate that Masimo Co. will post 4.04 earnings per share for the current fiscal year. About Masimo ( Free Report ) Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. Further Reading Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. ( NASDAQ:MASI – Free Report ). Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter .Banque Cantonale Vaudoise decreased its stake in shares of CEMEX, S.A.B. de C.V. ( NYSE:CX – Free Report ) by 32.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,743 shares of the construction company’s stock after selling 9,645 shares during the quarter. Banque Cantonale Vaudoise’s holdings in CEMEX were worth $120,000 at the end of the most recent quarter. A number of other institutional investors and hedge funds have also modified their holdings of CX. Allworth Financial LP increased its holdings in CEMEX by 36.0% during the third quarter. Allworth Financial LP now owns 6,606 shares of the construction company’s stock valued at $40,000 after buying an additional 1,747 shares during the last quarter. Legacy Wealth Asset Management LLC increased its stake in CEMEX by 3.6% in the 3rd quarter. Legacy Wealth Asset Management LLC now owns 75,949 shares of the construction company’s stock worth $463,000 after buying an additional 2,654 shares in the last quarter. 1832 Asset Management L.P. increased its stake in CEMEX by 13.9% in the 2nd quarter. 1832 Asset Management L.P. now owns 26,200 shares of the construction company’s stock worth $167,000 after buying an additional 3,200 shares in the last quarter. Private Advisor Group LLC increased its stake in CEMEX by 14.7% in the 3rd quarter. Private Advisor Group LLC now owns 26,831 shares of the construction company’s stock worth $164,000 after buying an additional 3,441 shares in the last quarter. Finally, Ballentine Partners LLC increased its stake in CEMEX by 14.5% in the 3rd quarter. Ballentine Partners LLC now owns 29,736 shares of the construction company’s stock worth $181,000 after buying an additional 3,777 shares in the last quarter. Institutional investors own 82.97% of the company’s stock. Wall Street Analysts Forecast Growth A number of brokerages have recently weighed in on CX. JPMorgan Chase & Co. lowered CEMEX from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $7.00 to $6.00 in a research report on Tuesday, October 29th. Royal Bank of Canada cut their price objective on shares of CEMEX from $6.50 to $6.00 and set a “sector perform” rating on the stock in a report on Tuesday, October 29th. Barclays cut their price objective on shares of CEMEX from $9.00 to $8.00 and set an “overweight” rating on the stock in a report on Tuesday, October 29th. Scotiabank cut their price objective on shares of CEMEX from $10.00 to $8.90 and set a “sector outperform” rating on the stock in a report on Tuesday, October 29th. Finally, StockNews.com lowered shares of CEMEX from a “strong-buy” rating to a “buy” rating in a report on Friday, October 11th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, CEMEX has a consensus rating of “Moderate Buy” and a consensus price target of $7.82. CEMEX Price Performance Shares of CX opened at $5.51 on Friday. The firm has a market capitalization of $7.98 billion, a PE ratio of 18.23 and a beta of 1.49. The company has a debt-to-equity ratio of 0.49, a current ratio of 0.98 and a quick ratio of 0.73. CEMEX, S.A.B. de C.V. has a 1-year low of $5.00 and a 1-year high of $9.27. The company’s fifty day moving average price is $5.84 and its 200-day moving average price is $6.37. CEMEX Cuts Dividend The firm also recently announced a Variable dividend, which was paid on Tuesday, September 24th. Investors of record on Friday, September 13th were given a dividend of $0.021 per share. The ex-dividend date was Friday, September 13th. This represents a yield of 0.7%. CEMEX’s dividend payout ratio is presently 13.33%. CEMEX Company Profile ( Free Report ) CEMEX, SAB. de C.V., together with its subsidiaries, produces, markets, distributes, and sells cement, ready-mix concrete, aggregates, urbanization solutions, and other construction materials and services worldwide. The company offers gray ordinary portland, white portland, oil-well, and blended cement products; mortar; and standard ready-mix, architectural and decorative, rapid-setting, fiber-reinforced, fluid-fill, roller-compacted, self-consolidating, pervious, and antibacterial, and other concrete products. Further Reading Want to see what other hedge funds are holding CX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CEMEX, S.A.B. de C.V. ( NYSE:CX – Free Report ). Receive News & Ratings for CEMEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEMEX and related companies with MarketBeat.com's FREE daily email newsletter .
Thousands of people across France are protesting against sexual violence to mark the International Day for Elimination of Violence Against Women. Women held banners reading "we won't serve the rearming of the state" and "sexist violence, fascist violence, same feminist fight". Dozens of others in Paris dressed as Second World War feminist symbol Rosie the Riveter. Femi Otitoju, a member of the campaign group Million Women Rise, told Sky News sexual violence had become "widespread". "What's really happening here is that we are getting a little bit of an insight into the every day, the banal violence that women face on a day-to-day basis," she said. More on France Protests across France call for end to 'sexist and misogynistic' culture amid mass rape trial Gisele Pelicot rape case: Victim accuses dozens of men alleged to have raped her of 'cowardice' Gisele Pelicot rape case: Sons face 'devil' father in court as they speak of disgust and 'lost childhood' Related Topics: France "It's an ongoing problem, an epidemic even, of violence against women and girls." She continued: "We should be shocked about how widespread [sexual violence] has become and how day-to-day attitudes towards women and girls are changing." Ms Otitoju took aim at social media personalities who advocate "very regressive and very dangerous attitudes" that are being adopted by young men. "We need to look at the way in which social media is addressing gender roles and the ways in which being known as a sexual predator isn't seen as a negative thing for a lot of people," she said. Ms Otitoju called on men to take action against sexual violence. "We want to see men taking responsibility, never keeping silent when they see violence against women and girls, and supporting women who are on the receiving end of this kind of behaviour." Please use Chrome browser for a more accessible video player Please use Chrome browser for a more accessible video player The protests were sparked by the ongoing Gisele Pelicot trial , in which 50 men stand accused of raping the 71-year-old while unconscious over a 10-year period. Her husband Dominique Pelicot, 72, has already admitted drugging and raping her and allowing other men to abuse her. Follow our channel and never miss an update Be the first to get Breaking News Install the Sky News app for free Most of the other men deny rape, claiming they thought she was asleep as part of roleplay. On Tuesday, Ms Pelicot told the court: "For me, this is the trial of cowardice, there is no other way to describe it." She went on: "It is time for society to look at this macho, patriarchal society and change the way it looks at rape."
Letter: HornbergerOK, so "brat" is out and "demure" is going to rule in 2024. The latter has been named word of the year, with searches for the word seeing a "meteoric rise" of some 1,200% between January and August. As reports, the spike in people who apparently don't know what demure means was largely driven by—you guessed it—a social influencer: TikToker Jools Lebron, who has some 2.3 million followers. "You see how I do my makeup for work? Very demure. Very mindful," goes one of the posts that inspired the likes of Kim Kardashian, RuPaul, and Jennifer Lopez to glom on. "The way I came to the interview is the way I go to the job. A lot of you girls go to the interview looking like Marge Simpson and go to the job looking like (her sisters) Patty and Selma. Not demure," Lebron says. Other words that made the shortlist:
CME Group Tour Championship Scores
Online Survey Software Market to Expand by USD 5.57 Billion (2024-2028), Driven by Demand for Real-Time Data Analysis, AI Redefining Market Landscape - Technavio
New Regulation: FuelEU Maritime Comes into Force on 1 JanuaryConexon Connect completes first fiber-to-the-home project in Florida, marking sixth broadband network completion nationwide
FREMONT, Calif. , Dec. 2, 2024 /PRNewswire/ -- Lam Research Corp. (Nasdaq: LRCX ). Today, the U.S. government announced additional measures to further restrict semiconductor technology exports to China . Our initial assessment is that the effect of the announced measures on Lam's business will be broadly consistent with our prior expectations. As a result, at this time we have no plans to update Lam's financial guidance for the December 2024 quarter as stated in our earnings press release on October 23, 2024 . About Lam Research Lam Research Corporation is a global supplier of innovative wafer fabrication equipment and services to the semiconductor industry. Lam's equipment and services allow customers to build smaller and better performing devices. In fact, today, nearly every advanced chip is built with Lam technology. We combine superior systems engineering, technology leadership, and a strong values-based culture, with an unwavering commitment to our customers. Lam Research (Nasdaq: LRCX ) is a FORTUNE 500® company headquartered in Fremont, Calif. , with operations around the globe. Learn more at www.lamresearch.com . (LRCX) Caution Regarding Forward-Looking Statements: Statements made in this press release that are not of historical fact are forward-looking statements and are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to but are not limited to the effect of U.S. government restrictions on semiconductor technology exports to China , the effect of such measures on Lam's business, and our outlook and guidance for future financial results. Some factors that may affect these forward-looking statements include: trade regulations, export controls, trade disputes, and other geopolitical tensions may inhibit our ability to sell our products; our understanding of newly announced trade restrictions and their impact on our business may change over time; business, political and/or regulatory conditions in the consumer electronics industry, the semiconductor industry and the overall economy may deteriorate or change; the actions of our customers and competitors may be inconsistent with our expectations; supply chain cost increases and other inflationary pressures have impacted and may continue to impact our profitability; supply chain disruptions or manufacturing capacity constraints may limit our ability to manufacture and sell our products; and natural and human-caused disasters, disease outbreaks, war, terrorism, political or governmental unrest or instability, or other events beyond our control may impact our operations and revenue in affected areas; as well as the other risks and uncertainties that are described in the documents filed or furnished by us with the Securities and Exchange Commission, including specifically the Risk Factors described in our annual report on Form 10-K for the fiscal year ended June 30, 2024 and quarterly report on Form 10-Q for the quarter ended September 29, 2024 . These uncertainties and changes could materially affect the forward-looking statements and cause actual results to vary from expectations in a material way. The Company undertakes no obligation to update the information or statements made in this press release. Company Contacts: Ram Ganesh Investor Relations (510) 572-1615 Email: [email protected] Source: Lam Research Corporation### SOURCE Lam Research CorporationNEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against WM Technology, Inc. (“WM Technology” or “the Company”) (NASDAQ: MAPS) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired WM Technology securities between May 25, 2021, and September 24, 2024, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/MAPS . Case Details The complaint alleges that Defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose, among other things, that: (1) WM Technology's monthly average user metrics (MAUs) were severely inflated for years; and (2) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. What's Next? A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/MAPS or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in WM Technology you have until December 16, 2024, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. There is No Cost to You We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful. Why Bronstein, Gewirtz & Grossman Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Nathan Miller 332-239-2660 | info@bgandg.com
NoneLakers vs Nuggets Prediction: Odds, Expert Picks, Projected Starting Lineups, Betting Trends and Stats
Bellingham brothers ‘sign’ 10-year contract with BurnleyBaby kept in a drawer for almost three years ‘had never seen daylight’ as mum jailed over ‘extreme neglect’